Five years of EMA-approved systemic cancer therapies for solid tumours:a comparison of two thresholds for meaningful clinical benefit
Autor: | Katharina Rosian, Sarah Wolf, Nicole Grössmann, Richard Sullivan, J.C. Del Paggio, Robert Emprechtinger, Claudia Wild, Christopher M. Booth |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Cancer Research
medicine.medical_specialty Meaningful Use Time Factors MEDLINE Alternative medicine ESMO-MCBS Antineoplastic Agents Benefit Medical Oncology Lower limit 03 medical and health sciences 0302 clinical medicine Neoplasms Outcome Assessment Health Care Health care medicine Humans 030212 general & internal medicine Intensive care medicine Societies Medical health care economics and organizations business.industry Health technology assessment (HTA) Hazard ratio Cancer 610 Medical sciences Medicine medicine.disease Confidence interval ddc: 610 Oncology 030220 oncology & carcinogenesis Relative risk business Cancer drug approval Value |
Zdroj: | Grössmann, N, Del Paggio, J C, Wolf, S, Sullivan, R, Booth, C M, Rosian, K, Emprechtinger, R & Wild, C 2017, ' Five years of EMA-approved systemic cancer therapies for solid tumours : a comparison of two thresholds for meaningful clinical benefit ', European Journal of Cancer, vol. 82, pp. 66-71 . https://doi.org/10.1016/j.ejca.2017.05.029 Brücken bauen-von der Evidenz zum Patientenwohl; 19. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin; 20180308-20180310; Graz, Österreich; DOC18ebmV-07-2 /20180306/ |
Popis: | Objective: Several societies have proposed frameworks that attempt to support the optimal use of limited health care resources, while offering a standardised and transparent tool to evaluate the benefit of novel cancer therapies. One prominent tool is the European Society for Medical Oncology Magnitude[for full text, please go to the a.m. URL] Brücken bauen – von der Evidenz zum Patientenwohl; 19. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin |
Databáze: | OpenAIRE |
Externí odkaz: |